NCT07459257 Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis
| NCT ID | NCT07459257 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Elazığ Mental Health and Diseases Hospital |
| Condition | Methamphetamine Induced Psychosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-02-03 |
| Primary Completion | 2025-07-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2025-02-03 with a primary completion date of 2025-07-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed/will be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed/will be assessed monthly using standardized psychometric instruments. The study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.
Eligibility Criteria
* Methamphetamine-Induced Psychotic Disorder (MP) Group: \*Inclusion Criteria: * Diagnosis of MP according to DSM-5-TR * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent * Methamphetamine-Induced Psychotic Disorder (MP) Group: * Exclusion Criteria: * Hypertension * Diabetes mellitus * Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MP * Alcohol use disorder
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07459257 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 65 Years, studying Methamphetamine Induced Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07459257 currently recruiting?
Yes, NCT07459257 is actively recruiting participants. Contact the research team at mhorum@hotmail.com for enrollment information.
Where is the NCT07459257 trial being conducted?
This trial is being conducted at Elâzığ, Turkey (Türkiye).
Who is sponsoring the NCT07459257 clinical trial?
NCT07459257 is sponsored by Elazığ Mental Health and Diseases Hospital. The trial plans to enroll 150 participants.